2407 — Gaush Meditech Income Statement
0.000.00%
Last trade - 00:00- HK$1.30bn
- HK$1.41bn
- CNY1.43bn
- 90
- 79
- 78
- 97
Annual income statement for Gaush Meditech, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 962 | 1,298 | 1,254 | 1,406 | 1,428 |
| Cost of Revenue | |||||
| Gross Profit | 436 | 609 | 625 | 692 | 663 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 810 | 1,353 | 1,486 | 1,108 | 1,236 |
| Operating Profit | 152 | -54.4 | -232 | 298 | 192 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 149 | -138 | -275 | 248 | 155 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 98.5 | -192 | -353 | 173 | 88.5 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 99.4 | -190 | -350 | 174 | 92.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 99.4 | -190 | -350 | 174 | 92.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.672 | -1.18 | -3.34 | 1.17 | 0.715 |
| Dividends per Share |